Atricure, INC. (ATRC) — SEC Filings

Q: What are the key financial highlights for Atricure, INC.?

Key financial highlights for Atricure, INC. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Atricure, INC.?

Key executives at Atricure, INC. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Atricure, INC. stock?

Risk factors for Atricure, INC. (ATRC) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Atricure, INC.?

Forward-looking statements and predictions from Atricure, INC. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Atricure, INC.. Recent DEFA14A filing on Apr 6, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Atricure, INC. on SEC EDGAR

Overview

Atricure, INC. (ATRC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 6, 2026: AtriCure, Inc. filed a Definitive Additional Materials (DEFA14A) on April 6, 2026, related to proxy materials. The filing includes various documents such as a proxy notice and graphic files, likely for a shareholder meeting. The company is based in Mason, Ohio, and operates in the Surgical & Medical

Sentiment Summary

Across 33 filings, the sentiment breakdown is: 1 bearish, 29 neutral, 3 mixed. The dominant filing sentiment for Atricure, INC. is neutral.

Filing Type Overview

Atricure, INC. (ATRC) has filed 4 DEFA14A, 6 10-Q, 2 8-K/A, 13 8-K, 1 DEF 14A, 2 10-K, 1 SC 13G, 4 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (33)

AtriCure Files Definitive Proxy Materials — DEFA14A · Apr 6, 2026 Risk: low
AtriCure, Inc. filed a Definitive Additional Materials (DEFA14A) on April 6, 2026, related to proxy materials. The filing includes various documents such as a p
AtriCure Narrows Losses on Strong 15.8% Revenue Growth — 10-Q · Oct 30, 2025 Risk: medium
AtriCure, Inc. reported a significant increase in revenue for the three months ended September 30, 2025, reaching $134.269 million, up from $115.910 million in
AtriCure Files 8-K/A Amendment — 8-K/A · Oct 29, 2025 Risk: low
AtriCure, Inc. filed an 8-K/A amendment on October 29, 2025, to report results of operations and financial condition, as well as financial statements and exhibi
AtriCure's Q2 Filing Shows Equity Shifts, European Presence — 10-Q · Jul 30, 2025 Risk: medium
AtriCure, Inc. (ATRC) filed its 10-Q for the period ending June 30, 2025, indicating a continued focus on surgical and medical instruments. While specific reven
AtriCure, Inc. Files 8-K on Financials — 8-K · Jul 29, 2025 Risk: low
On July 29, 2025, AtriCure, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as fina
AtriCure, Inc. Files 8-K: Director/Officer Changes & Shareholder Votes — 8-K · May 20, 2025 Risk: medium
AtriCure, Inc. filed an 8-K on May 20, 2025, reporting on events from May 19, 2025. The filing covers the departure of directors or officers, election of direct
AtriCure Files Definitive Proxy Statement — DEFA14A · May 5, 2025 Risk: low
AtriCure, Inc. filed a Definitive Proxy Statement (DEFA14A) on May 5, 2025. This filing is related to the company's proxy materials, which are used to solicit v
AtriCure, Inc. Files Q1 2025 10-Q — 10-Q · Apr 30, 2025 Risk: medium
AtriCure, Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial information and business operations for the first quarter of 20
AtriCure, Inc. Files 8-K on Financials — 8-K · Apr 29, 2025 Risk: low
AtriCure, Inc. filed an 8-K on April 29, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhibits. The
AtriCure Inc. Executive Compensation & Stock Awards Revealed — DEF 14A · Apr 7, 2025 Risk: medium
AtriCure, Inc. filed its DEF 14A on April 7, 2025, detailing executive compensation and stock awards for the fiscal year ending December 31, 2024. The filing in
AtriCure, Inc. Files 8-K with Regulation FD Disclosure — 8-K · Mar 26, 2025 Risk: low
On March 26, 2025, AtriCure, Inc. filed an 8-K report. The filing indicates a Regulation FD Disclosure, meaning the company is providing material information to
AtriCure, Inc. Files 2024 10-K — 10-K · Feb 14, 2025 Risk: medium
AtriCure, Inc. filed its 2024 10-K on February 14, 2025, detailing its fiscal year ending December 31, 2024. The company, based in Mason, Ohio, operates in the
AtriCure, Inc. Files 8-K on Financials — 8-K · Feb 12, 2025 Risk: low
AtriCure, Inc. filed an 8-K on February 12, 2025, reporting on its Results of Operations and Financial Condition, as well as Financial Statements and Exhibits.
AtriCure, Inc. Files 8-K on Financials — 8-K · Jan 13, 2025 Risk: low
AtriCure, Inc. filed an 8-K on January 13, 2025, reporting on its Results of Operations and Financial Condition, Regulation FD Disclosure, and Financial Stateme
SC 13G Filing — SC 13G · Nov 14, 2024
AtriCure, Inc. Files Q3 2024 10-Q Report — 10-Q · Oct 30, 2024 Risk: low
AtriCure, Inc. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the third quarter o
AtriCure, Inc. Files 8-K on Financials — 8-K · Oct 29, 2024 Risk: low
AtriCure, Inc. filed an 8-K on October 29, 2024, reporting on its results of operations and financial condition, as well as financial statements and exhibits. T
AtriCure, Inc. Files Q2 2024 10-Q — 10-Q · Jul 31, 2024 Risk: medium
AtriCure, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported financial results for the second quarter and the first half of the year,
AtriCure, Inc. Files 8-K on Financials — 8-K · Jul 30, 2024 Risk: low
AtriCure, Inc. filed an 8-K on July 30, 2024, reporting on its financial condition and results of operations. The filing includes financial statements and exhib
AtriCure Adds Directors, Adopts New Equity Plans — 8-K · May 14, 2024 Risk: low
On May 13, 2024, AtriCure, Inc. filed an 8-K report detailing several key events. The company announced the election of two new directors, Dr. Michael J. Cima a
AtriCure, Inc. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 2, 2024 Risk:
AtriCure, Inc. (ATRC) filed a Quarterly Report (10-Q) with the SEC on May 2, 2024. AtriCure, Inc. filed a 10-Q report for the period ending March 31, 2024. The
AtriCure, Inc. Files 8-K on Operations and Financials — 8-K · May 1, 2024 Risk: low
On May 1, 2024, AtriCure, Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condition, as well as financ
AtriCure Files Definitive Proxy Statement — DEFA14A · Apr 23, 2024 Risk: low
AtriCure, Inc. filed a definitive proxy statement on April 3, 2024, regarding its annual meeting. The filing is a DEFA14A, indicating it's a definitive addition
AtriCure Files Proxy Materials for Annual Meeting — DEFA14A · Apr 3, 2024 Risk: low
AtriCure, Inc. filed a Definitive Additional Materials proxy statement on April 3, 2024. This filing relates to the company's annual meeting of stockholders, wh
AtriCure Amends Officer Changes & Compensation Filing — 8-K/A · Feb 27, 2024 Risk: low
AtriCure, Inc. filed an 8-K/A Amendment No. 1 on February 27, 2024, pertaining to an original event reported on January 4, 2024. The amendment relates to items
AtriCure, Inc. Files 2023 Annual Report on Form 10-K — 10-K · Feb 16, 2024 Risk: medium
AtriCure, Inc. (ATRC) filed a Annual Report (10-K) with the SEC on February 16, 2024. AtriCure, Inc. filed its 2023 Form 10-K on February 16, 2024. The company
AtriCure Files 8-K on Financial Results and Operations — 8-K · Feb 15, 2024 Risk: low
AtriCure, Inc. filed an 8-K on February 15, 2024, to report its results of operations and financial condition, along with related financial statements and exhib
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
Invesco Cuts AtriCure Stake to 9.9% as of Dec 29, 2023 — SC 13G/A · Feb 1, 2024
Invesco Ltd. filed an amended SC 13G/A on February 1, 2024, disclosing its ownership in AtriCure Inc. (NASDAQ: ATRC) as of December 29, 2023. This filing indica
BlackRock Amends AtriCure Stake: 13G/A Filing Shows Ownership Update — SC 13G/A · Jan 25, 2024
BlackRock, Inc. has filed an Amendment No. 7 to its Schedule 13G, indicating a change in its beneficial ownership of AtriCure, Inc. common stock as of December
AtriCure Reports Material Agreement Changes & New Financial Obligation — 8-K · Jan 8, 2024
AtriCure, Inc. filed an 8-K on January 8, 2024, reporting an event that occurred on January 5, 2024, concerning the entry into and termination of a material def
AtriCure 8-K Signals Potential Leadership/Comp Changes — 8-K · Jan 4, 2024
AtriCure, Inc. filed an 8-K on January 4, 2024, to report an event concerning the departure or election of directors or officers and compensatory arrangements.

Risk Profile

Risk Assessment: Of ATRC's 25 recent filings, 0 were flagged as high-risk, 8 as medium-risk, and 17 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Atricure, INC.'s most recent 10-Q filing (Oct 30, 2025):

Revenue: $394.028M
Net Income: $(13.204)M
EPS: $(-0.28)
Debt-to-Equity: 0.33
Cash Position: $147.865M
Operating Margin: -3.0%
Total Assets: $635.442M
Total Debt: $61.865M

Key Executives

Chief Executive Officer
Dr. Michael J. Cima
Mr. David M. D. Smith

Industry Context

AtriCure operates in the highly competitive medical device market, specifically focusing on solutions for atrial fibrillation and left atrial appendage closure. The industry is characterized by rapid technological advancements, stringent regulatory oversight, and a need for strong clinical evidence to drive adoption. Key trends include the shift towards minimally invasive procedures and the increasing demand for innovative therapies to address cardiovascular diseases.

Top Tags

financial-reporting (6) · financials (5) · medical-devices (4) · 10-Q (4) · Medical Devices (3) · amendment (3) · corporate-governance (3) · proxy-statement (3) · regulatory-filing (3) · 8-k (3)

Key Numbers

Revenue for Q3 2025: $134.269M — Increased by 15.8% from $115.910 million in Q3 2024
Revenue for nine months ended Sept 30, 2025: $394.028M — Increased by 15.5% from $341.030 million in the prior year period
Income from operations for Q3 2025: $0.208M — Significant improvement from a $7.405 million loss in Q3 2024
Net loss for Q3 2025: $(0.267)M — Reduced from a net loss of $7.853 million in Q3 2024
Net loss for nine months ended Sept 30, 2025: $(13.204)M — Reduced from a net loss of $29.130 million in the prior year period
Cash and cash equivalents as of Sept 30, 2025: $147.865M — Increased from $122.721 million at Dec 31, 2024
Net cash provided by operating activities for nine months ended Sept 30, 2025: $37.307M — Increased from $6.368 million in the prior year period
Accumulated deficit as of Sept 30, 2025: $414.959M — Indicates historical unprofitability
Common shares outstanding as of Oct 27, 2025: 49,716,988 — Reflects total shares outstanding
Long-term debt as of Sept 30, 2025: $61.865M — Due upon maturity of the ABL Facility on January 5, 2027
Reporting Period End Date: 2025-06-30 — The period covered by this 10-Q filing.
Filing Date: 2025-07-30 — The date the 10-Q was officially filed with the SEC.
Central Index Key (CIK): 0001323885 — Unique identifier for AtriCure, Inc. with the SEC.
Form Type: 10-Q — The type of SEC filing, indicating a quarterly report.
SIC Code: 3841 — Standard Industrial Classification for Surgical & Medical Instruments & Apparatus.

Frequently Asked Questions

What are the latest SEC filings for Atricure, INC. (ATRC)?

Atricure, INC. has 33 recent SEC filings from Jan 2024 to Apr 2026, including 13 8-K, 6 10-Q, 4 DEFA14A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of ATRC filings?

Across 33 filings, the sentiment breakdown is: 1 bearish, 29 neutral, 3 mixed. The dominant sentiment is neutral.

Where can I find Atricure, INC. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Atricure, INC. (ATRC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Atricure, INC.?

Key financial highlights from Atricure, INC.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for ATRC?

The investment thesis for ATRC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Atricure, INC.?

Key executives identified across Atricure, INC.'s filings include Chief Executive Officer, Dr. Michael J. Cima, Mr. David M. D. Smith.

What are the main risk factors for Atricure, INC. stock?

Of ATRC's 25 assessed filings, 0 were flagged high-risk, 8 medium-risk, and 17 low-risk.

What are recent predictions and forward guidance from Atricure, INC.?

Forward guidance and predictions for Atricure, INC. are extracted from SEC filings as they are enriched.